New anesthesia drug tested for safer surgery in endometrial cancer patients

NCT ID NCT07372209

Completed Symptom relief Sponsor: Tangshan Maternal and Child Health Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether oliceridine, a newer painkiller, is as safe and effective as the standard drug sufentanil for putting patients to sleep before gynecologic laparoscopic surgery. 120 women with endometrial cancer took part. Researchers monitored blood pressure and heart rate changes during anesthesia induction and tracked any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oliceridine and sufentanil (analgesic drugs used for anesthesia)
What this could lead to: If oliceridine proves safer or more stable than sufentanil, it could offer a better option for anesthesia induction in gynecologic surgeries.
What could go wrong: This is a small, completed study with 120 participants, so results may not apply broadly. The drugs are already approved, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERAL ANESTHETIC GYNECOLOGICAL LAPAROSCOPIC SURGERY INTUBATION

Contacts and locations

Locations

Tangshan Maternal and Child Health Hospital

Tangshan, Hebei, 063000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.